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Abstract

Bacteremia refers to bacterial presence in the blood. Bacterial proliferation in the
blood requires that the organism adapt its metabolism to available nutrients.
Nucleotide precursors that could be used are present at low levels in the blood, and
thus the invading bacteria must rely on de novo nucleotide biosynthesis for survival.
The dihydroorotase domain is a key enzyme in pyrimidine biosynthesis and a
promising drug target. The genes encoding the dihydroorotase (DHOase) and
aspartate transcarbamoylase (ATCase) of Bacillus anthracis (B. anthracis) were
cloned for expression in Escherichia coli (E. coli). The proteins were purified by affinity
chromatography and the enzymatic activity was determined by enzyme assays. The
data suggests that a physical and functional interaction exists. The activity of ATCase
was increased by about 2 fold in the presence of an equimolar concentration of
DHOase. An ATCase-DHOase complex was formed as judged by S-300 gel filtration
chromatography and cross-linking methods. Moreover, orotate was found to be an
effective inhibitor of the DHOase activity at nanomolar concentrations. These results
bring us closer to understanding the structural organization of the pyrimidine pathway
in the pathogenic B. anthracis bacterium and provide a lead in the design of drugs
selective to the bacteria.
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1. Introduction

1.1 Bacteremia

The presence of bacteria in the bloodstream is referred to as bacteremia, a
major cause of morbidity and mortality worldwide.

[1, 2]

The growth of bacterial

pathogens in the blood represents one of the most dangerous stages of infection. The
B. anthracis infection is characterized by the rapid growth of the bacteria in the host’s
3

blood, reaching up to108 bacteria/ml. Bacteremia often leads to severe illness and
death.

While growing in the blood, bacteria do not only attempt to evade the immune
response of the host, but also adjust their metabolism to suit the availability of
nutrients. For the proliferation of bacterial pathogens in human blood, bacteria need
to synthesize metabolites that are present in limiting concentrations. For that, they
need to produce specific enzymes that are critical for the growth of the bacteria in the
bloodstream. Certain nutrients are scarce in the blood and need to be synthesized de
novo by the proliferating bacteria in the blood. E. coli is a major cause of Gramnegative bacteremia in hospitalized patients. A recent comprehensive, genome-wide
4

search for genes that are essential for growth in human serum showed that a
majority of the mutants identified consistently carried a deletion of a gene involved in
either the purine or pyrimidine nucleotide biosynthetic pathway.

1

The limited supply of nucleotide precursors appears to be the key limitation for
bacterial growth in serum. Inactivation of genes involved in nucleotide biosynthesis led
to significant growth defects in human serum not only for E. coli but also for
Salmonella Typhimurium and
B. anthracis. The study clearly
shows that de novo nucleotide
biosynthesis represents the
single most critical metabolic
need for bacterial growth in
blood and is likely to be the
only metabolic pathway that is
indispensible for bacterial
pathogens invading the blood.
The corresponding enzymes
involved in nucleotide
biosynthesis are thus
promising antibiotic targets for
reducing bacterial growth and
the treatment of bloodstream
infections.

More specifically, of the
enzymes identified to be
Figure 1: Genes involved in the purine and pyrimidine biosynthetic pathways.

2

essential for growth of pathogenic bacteria in human blood, two, PyrC and PurE, are
especially attractive as targets for antibiotics. PyrC encodes dihydroorotase that
catalyzes the reversible cyclization of carbamoyl aspartate to dihydroorotate in the
5

third step of the pyrimidine biosynthesis pathway (Figure 1).

A detailed examination of PyrC and PurE gene products, as well as other
enzymes of the nucleotide biosynthesis pathways, as potential antibiotic targets may
ultimately lead to the development of new therapies for treatment of bacterial
bloodstream infections.

1.2 Anthrax
6

Anthrax is a life-threatening infectious disease that is very often lethal. It can
affect animals and humans and is caused by the bacterium Bacillus anthracis.
Anthrax does not spread from person to person. However, the disease can spread
from diseased animals to humans by directly contacting the diseased animal or by
food consumption of the infected animals. Anthrax is spread by spores, such as via
air inhalation, but does not spread directly from an infected animal or person to
another.

Anthrax organisms in the soil are dormant in the form of endospores or spores,
which are difficult to destroy and able to survive in harsh and extreme conditions for a
long period of time lasting as long as 48 years.

Spores may reactivate and multiply rapidly upon inhalation, ingestion, or
contact of spores with skin lesions on the host. If anthrax spores are inhaled, they can
3

migrate and proliferate in the lymph glands in the chest area, leading to them
spreading within the body. Death is often the end result due to toxin production.

More recently, anthrax has received a lot of attention as its spores can be
produced in vitro and used as a biological weapon. Funding is available for anthrax
research as the U.S. government largely lacks the range of medical countermeasures
needed to protect citizens from anthrax and other potential bioweapons.

Anthrax causes three forms of disease: cutaneous anthrax, inhalation anthrax,
and gastrointestinal (bowel) anthrax.

1.2.1 Cutaneous (skin) anthrax: This form of anthrax most commonly results when
humans handle the products of diseased animals. It normally begins as a reddish
spot that becomes enlarged and hardened. Lymph glands present in the area may
become swollen. Symptoms can include muscle aches, pain, fever, and headaches.
This form of anthrax is typically resolved in about six to seven weeks.

1.2.2 Inhalation anthrax: The first symptoms are subtle, gradual, and flu-like and
may develop in one to six days. These may include sore throat, fever, and muscle
pain. However, in a few days, the illness worsens and may result in severe respiratory
distress. Shock, coma, and death may follow. Even upon aggressive treatment, once
severe symptoms develop, 45% to 80% of patients typically die, and if left completely
untreated, the death rate can exceed 99%.

1.2.3 Gastrointestinal anthrax: This form is rare. It is caused by consumption of
infected, contaminated, or undercooked meat. The symptoms include nausea, bloody
4

diarrhea, loss of appetite, fever, and abdominal pain. Once the anthrax bacteria
invade the bowel wall, septicemia may result, where the infection spreads via the
bloodstream throughout the body with deadly toxicity.

1.2.4 Antibiotic therapy: Currently existing drugs are mainly effective if treatment is
started early enough. Common antibiotics such as penicillin, tetracycline, and
ciprofloxacin, are used to treat the cutaneous form of anthrax. Antibiotics delivered
early via intravenous therapy are typically employed continuously for the pulmonary
inhalation form.

1.3 Bacillus Anthracis (B. anthracis)

B. anthracis is a spore-forming bacterium that can be grown under aerobic or
anaerobic conditions. It is a Gram-positive, rod-shaped bacterium that is about 11.2µm wide and 3-5µm long. It is the only bacterium, thus far, known to synthesize a
protein capsule. The spores of the bacteria are highly resilient and can survive and
withstand low nutrient environments and extremes of temperatures for centuries.

1.4 The Pyrimidine Biosynthetic Pathway

Pyrimidine nucleotides play a critical role in cellular metabolism. They serve as
activated precursors of RNA and DNA, CDP-diacylglycerol phosphoglyceride for the
assembly of cell membranes, and UDP-sugars for protein glycosylation and glycogen
synthesis. There are two routes to the synthesis of pyrimidines; nucleotides can be
recycled by the salvage pathways or synthesized de novo from small metabolites.

5

Most cells have several specialized passive and active transporters that allow the
reutilization of preformed pyrimidine nucleosides and bases.

The de novo pyrimidine biosynthetic pathway (Figure 2) is indispensable in
proliferating cells in order to meet the increased demand for nucleic acid precursors
and other cellular
De nov o pyri mi din e bio s ynth es is

components. Pyrimidine
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Figure 2: The de novo pyrimidine biosynthesis pathway.

diabetes, and autoimmune
diseases, such as rheumatoid arthritis.

1.4.1 Aspartate Transcarbamoylase (ATCase): ATCase catalyzes the reaction of
carbamoyl phosphate and aspartate to form carbamoyl aspartate (Figure 2). In
mammalian cells, CAD is a multifunctional protein that catalyzes the first three steps of
the pyrimidine biosynthetic pathway. The carbamoyl phosphate synthetase (CPSase)
domain catalyzes the first step in the pathway. The ATCase domain is unregulated
and catalyzes the second step in the pathway. The isolated CAD ATCase domain is a
7

homotrimer of 34-kDa subunits. Kinetic and modeling studies showed that the
mammalian domain shares a common catalytic mechanism, oligomeric structure, and

6

tertiary-fold with the E. coli ATCase catalytic subunit,

(8-11)

including a composite

active site comprised of residues from adjacent subunits. The trimeric ATCase
interactions are a crucial organizing element in the CAD hexamer.

1.4.2 Dihydroorotase (DHOase): The DHOase domain catalyzes the third step in the
pathway, the reversible condensation of carbamoyl aspartate to dihydroorotate (Figure
2). It is a zinc metalloenzyme. The active site of E. coli DHOase has two zinc ions
and a carboxylysine that bridges the metal centers.

12

DHOases are classified

13

into

two major classes. Type I DHOases are the most ancient and include domains of
multifunctional proteins, such as CAD, subunits of multienzyme complexes, and
monofunctional enzymes. The type II enzymes, such as E. coli DHOase, are a more
recent evolutionary development and are smaller in size. The isolated CAD DHOase
domain has only one zinc atom and is larger than its bacterial counterpart, consistent
with its assignment as a type I DHOase.

(14-17)

The forward DHOase reaction is

favored at low pH (below pH 6), and the reverse reaction is favored at high pH (above
pH 8).

1.5 B. anthracis DHOase

The isolated DHOase from B. anthracis is a homodimer.

18

The secondary

structure of two chains is identical, with two zinc atoms in each chain and a total of
180 water molecules. An overall tertiary structure is formed from the TIM-barrel
secondary structure motif.

7

18

The active site of the enzyme includes a binuclear Zn center.

His59, His61,

Asp151, and Asp304 are bound to the more buried α Zn atom while His178, His231,
and Asp151 bind to the β Zn atom. Asp151, via its carboxylate side group, forms a
bridge between the two Zinc atoms, separated by 3.3 Å. There is a large interface in
the structure between the monomers, which involves 18 residues from one chain and
17 residues from the other (Figure 3).

18

Figure 3: Homodimer of the dihydroorotase from B. anthracis at 2.6 Å resolution

8

1.6 Aquifex Aeolicus (A. aeolicus)

A. aeolicus is a rod-shaped hyperthermophilic bacterium of ancient lineage. It
grows best in water between 85-95 ºC. It is found near volcanoes and hot springs.
The genome of A. aeolicus is only about a third of that of E. coli.

1.7 Sequence homology of B. anthracis and A. aeolicus DHOase
The DHOase from B. anthracis is highly conserved in sequence to that of A.
aeolicus. The percent sequence identity is 43% (Figure 4).
Score = 321 bits (822), Expect = 3e-89, Method: Compositional matrix adjust.
Identities = 182/426 (43%), Positives = 257/426 (61%), Gaps = 10/426 (2%)
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Figure 4: Sequence homology of B. Anthracis and A.aeolicus DHOase
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1.8 DHOase from A. aeolicus

Unlike the DHOase from E. coli and B. anthracis, the DHOase from A. aeolicus
has a single zinc ion (Figure 5) present only in the α site. Moreover, the structure has
three disordered surface loops near the active site and a complete composite domain
involving both N-terminal and C-terminal segments.

19

Figure 5: Three-dimensional structure and active site of A. aeolicus DHOase

The isolated A. aeolicus DHOase domain is catalytically inactive (Figure 5) despite the
presence of the zinc and all of the active site residues needed for catalysis. That
activity is completely regained, however, upon association with A. aeolicus ATCase.
A 1:1 stoichiometric complex of A. aeolicus DHOase and ATCase can be reconstituted
and is fully active.

19

10

Figure 6: Model for the assembly of the A. aeolicus DHOase-ATCase complex.

Both the DHOase and ATCase monomers are inactive. A mode for the
complex formation may be that the ATCase associates form a catalytically active
trimer, which then associates with the DHOase monomers to form a hexamer that has
both DHOase and ATCase activities (Figure 6).

The 1:1 stoichiometric complex was found to exist as an equilibrium mixture of
(ATCase)3(DHOase)3 hexamers and ((ATC)3(DHOase)3)2 dodecamers.

19

Significantly, the DHOase component, as well as the ATCase, in the complex is
catalytically active.

Interestingly, while the DHOase appears to rely on the ATCase for its catalytic
activity, the converse does not appear to be true as the A. aeolicus ATCase is not
activated by DHOase.

11

1.9 A stoichiometric complex (DAC) of A. aeolicus DHOase and ATCase

A stoichiometric complex of A. aeolicus DHOase forms with ATCase in a
hollow, hetero-dodecamer (Figure 7), in which all 12 enzyme active sites face an
aqueous cavity with limited access to the exterior. This amazing architecture may
facilitate allosteric communication between the active sites and possibly increases the
net production of dihydroorotate, which is thermodynamically unfavored at
physiological pH.

The three active site loops that are intrinsically disordered in the free, inactive
DHOase, described above, are ordered in the DAC complex.

Figure 7: The DAC dodecamer

12

2. Research Goal and Objectives

The overall goal of this research work is to more thoroughly characterize the
second and third steps in de novo pyrimidine biosynthesis in B. anthracis and to gain a
better understanding of the structural and functional organization of the B. anthracis
ATCase and DHOase domains.

2.1 Significance of the Proposed Study

The DHOase has recently emerged as a promising drug target that may
ultimately lead to new therapies and pave the way for structure-based drug discovery
for treatment of Anthrax and other bacterial bloodstream infections.

2.2 Hypothesis

Anthrax ATCase and DHOase physically interact to form a dodecamer that
resembles that of A. aeolicus in structure and function.

2.3 Specific aims/goals

1) Identify whether the B. anthracis DHOase and ATCase form a physical complex.
This can be investigated by cross-linking and by determining the oligomeric structure
of the individual proteins and their mixtures by gel filtration chromatography. The
fractions can be collected from the column and analyzed by SDS-PAGE. Enzyme
activities will be determined by enzyme assays.

13

2) Explore the putative functional interactions of ATCase and DHOase. The proteins
will be mixed in different stoichiometric ratios and their activities measured by the
corresponding enzyme assays.

3) Study the effect of inhibitors previously used for the mammalian system, such as
Orotate, 5-amino-orotic acid, and 5-fluoro-orotic acid. Enzyme assays will be carried
out in the presence and absence of inhibitors.

14

3. Methods and Materials

3.1 Materials
Reagents including aspartate, carbamoyl aspartate, dihydroorotate, antipyrine,
diacetyl monoxime, carbamoyl phosphate used for enzyme assays, High Resolution
Sephacryl S-300 used for gel filtration chromatography, and the antibiotic ampicillin,
were all purchased from Sigma-Aldrich. The bacterial strain, BL21 (DE3), used for
expression of recombinant proteins and the bench mark prestained protein ladder,
were from Invitrogen.

3.2 Expression and Isolation of the Recombinant Proteins
Plasmid DNA encoding B. anthracis ATCase and DHOase were transformed
separately into the E. coli strain BL21 (DE3). The transformants were grown on agar
plates containing ampicillin. A single colony was selected and grown at 37 °C in an
overnight 15-ml culture consisting of LB medium and 100 µg/ml ampicillin. The
overnight culture was then inoculated into a 125-ml LB medium containing 100 µg/ml
of ampicillin and grown at 37oC. The cells were harvested and the pellet was
resuspended in 3 ml of 50 mM Tris/HCl, pH 8. The cells were disrupted by sonication
for 30 s in an ice/water bath for a total of five times with five minutes intervals to
prevent overheating. The cell extract was centrifuged at 14,000 rpm for 30 min at 4
°C, and the supernatant from the centrifuged fractions was collected and loaded onto
a 1-ml Ni2+-ProBond column equilibrated with 20 ml of 50 mM Tris/HCl, pH 8, 200
mM NaCl (TN buffer). The B. anthracis ATCase and DHOase were eluted with
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successive 3-ml aliquots of increasing concentrations of imidazole up to 300 mM in TN
buffer. The fractions were collected and analyzed by electrophoresis on 12% SDSPAGE gels and by enzyme activity assays.

3.3 ATCase Assay
The ATCase activity was determined by measuring the time dependent formation of
carbamoyl aspartate from carbamoyl phosphate and aspartate.

Carbamoyl phosphate

Carbamoyl aspartate
ATCase, Asp

The assay mixture consisted of 2 mM aspartate, 50 mM Tris/acetate buffer, pH 8.3,
and 2-3 µg of purified ATCase in a total volume of 1 ml. Samples were allowed to
preincubate at 37°C for 20 min. The reaction was then initiated by the addition of
100µl of 50 mM carbamoyl phosphate at 37oC and allowed to proceed for 10 min. The
reaction was then quenched with 1 ml of 5% acetic acid. A 2ml color mix which
contains antipyrine/diacetyl monoxime was added to generate a yellow color and the
assay mixture was heated at 60°C for 30-90 min for color development. The
carbamoyl aspartate generated by ATCase is converted into a yellow- colored
compound, and the absorbance was measured at 466 nm on a spectrophotometer.

3.4 DHOase Assay
The DHOase assay measured the reverse reaction, formation of carbamoyl aspartate
from dihydroorotate, as the equilibrium strongly favors dihydroorotate hydrolysis under
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the assay conditions. The formation of carbamoyl aspartate was quantitated at 466
nm, as described above.
Carbamoyl aspartate

dihydroorotate
DHOase

The assay mixture consisted of 2-3 µg of purified DHOase, 50 mM Tris/acetate, pH
8.3, and 10% glycerol, in a total volume of 1ml. The tubes were preincubated for 20
min at 37°C. The reaction was then initiated with 80 mM dihydroorotate and
quenched after 10 min of assay reaction by the addition of 1 ml 5% acetic acid. A
color mix consisting of 2 ml of the diacetyl monoxime/antipyrine reagent was added
and the assay mixture heated at 60 °C for 30-90min to generate a yellow color. The
samples were briefly cooled and the absorbance measured at 466 nm.

3.5 Formation of the ATCase-DHOase Complex

The complex was prepared by mixing ATCase and DHOase in 1:1 mole-mole ratio
followed by incubation on ice for 1 hr with gentle mixing.

3.6 Gel Filtration Chromatography

Proteins were eluted by size exclusion chromatography in decreasing order of size.
The oligomeric structure of the individual enzymes and the possible interaction
between them can be investigated using this technique. A 1.5 × 62 cm or 1.5 ×120
cm high resolution Sephacryl S-300 column was used in this study. Column beads
were cleaned with 0.5M NaOH for 2hr then equilibrated with 50mM Tris/acetate buffer,
pH 8.3. The flow rate of the column was 0.25 ml/min. Isolated ATCase or DHOase
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(0.6 ml, of 2-3 mg/ml) or mixed (0.6 ml, of 2-3 mg/ml) in an equimolar ratio were
loaded onto the column and allowed to flow through the column at a rate of 0.25
ml/min. The fractions were collected and analyzed by 12% SDS-PAGE gel
electrophoresis and by enzyme assays.

3.7 Inhibition Studies

5-amino orotic acid, orotic acid, and 5-fluro orotic acid were used as inhibitors of the
DHOase activity.
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4. Results and Discussion

4.1 Expression of B. Anthracis Proteins
Plasmids encoding the B. anthracis proteins were expressed in E. coli BL21 (DE3)
and the expressed proteins purified by affinity chromatography. Proteins were applied
to a Ni2+ affinity chromatography resin and eluted with different imidazole
concentrations. The fractions were analyzed for protein purity using SDS-PAGE.
Purified B. anthracis ATCase and DHOase were typically obtained in the 200 mM
imidazole/TN buffer (Figure 8). The purity of DHOase, 48 kDa, eluted with 200 mM
imidazole, was judged greater than 90% by SDS-PAGE. The concentration of the
purified protein, determined by the Lowry assay, ranged between 0.5 - 2.0 µg/µl.

Anthrax DHOase
Expression and Affinity Chromatography

180 kDaà
115 kDaà

DHOase

82 kDaà
64 kDaà
49 kDaà
37 kDaà

48 KDa

26 kDaà
19 kDaà

15 kDaà

L

Su FT

W1

W2

I50

I100

I200

I300

I400

Figure 8: SDS-Page of B. anthracis DHOase expression and
2+
purification by Ni affinity chromatography. Purified DHOase,
48 kDa, was eluted with 200 mM imidazole (I200).
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Purified B. anthracis ATCase (Figure 9), 36 kDa, was eluted with 200 mM
imidazole. The concentration of the protein ranged between 0.5- 2.0 µg/µl as
determined by the Lowry assay using BSA as the standard.

Anthrax ATCase
Expression and Affinity Chromatography

180 kDaà
115 kDaà
82 kDaà
64 kDaà
49 kDaà
37 kDaà

ATCase
36 KDa

26 kDaà
19 kDaà
15 kDaà

L

So

Su FT

W1

W2

I50

I100

I200

I300

Figure 9: SDS-Page of B. anthracis ATCase expression and purification
2+
by Ni affinity chromatography. Purified ATCase, 36 kDa, was eluted with
200 mM imidazole (I200).

4.2 Enzymatic Assay of DHOase
The activity of DHOase (Figure 10) was determined by measuring the formation of
carbamoyl aspartate at 37oC. The biosynthetic conversion of N-carbamoyl-L-aspartate
to dihydro-L-orotate was also measured spectrophotometrically. The concentration of
carbamoyl aspartate was calculated from a standard curve of known concentrations of
carbamoyl aspartate. The 1-ml reaction mixture contained 50 mM Tris/acetate, pH
8.3, 1% glycerol, varying concentrations of dihydroorotate and 4.8 µg purified
DHOase. The reaction mixture was pre-equilibrated for 20 min at 37oC and then
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initiated by the addition of the substrate dihydroorotate or protein and quenched with
5% acetic acid after 20 min reaction time. A 2 ml color mix which contained a 1:2
(volume: volume) ratio of diacetyl monoxime and antipyrine was then added, and the
tubes were incubated at 60°C for 30-90 min for yellow color development. The
absorbance was measured at 466 nm. The linear increase in absorbance due to the
formation of carbamoyl aspartate from dihydroorotate was followed. The equilibrium
strongly favors dihydroorotate hydrolysis.
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0.035
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0.025
0.02
0.015
0.01
0.005
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7

8

9

Dihydroorotate (mM)
Figure 10: Dihydroorotate saturation curve of isolated B. anthracis
DHOase.

4.3 Enzyme Assay of ATCase
The ATCase activity (Figure 11) was determined by measuring the formation of
carbomyl aspartate from carbamoyl phosphate and aspartate. The 1 ml assay
reaction consisted of 2 mM aspartate, 50 mM Tris/acetate, pH 8.3, 1% glycerol, 5 mM
21

carbamoyl phosphate, and 2 µg of purified protein. The reaction mixture was prewarmed for 20 min at 37oC and then initiated with either the protein or the substrate,
carbamoyl phosphate. The reaction was allowed to proceed for 20 min and was then
quenched with 1 ml 5% acetic acid. After the reaction was quenched, a 2 ml color mix
consisting of a 1:2 (volume: volume) ratio of diacetylmonoxime and antipyrine was
added and the mixture incubated at 60°C for 30-90 min for color development. The
absorbance was then measured spectrophotometrically at 466 nm and the amount of
carbamoyl aspartate formed calculated from the carbamoyl aspartate standard curve.
The free Bacillus anthracis ATCase is active by itself. The increased information of
carbamoyl aspartate from Carbamoyl phosphate was followed.
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ATCase (µg)
Figure 11: ATCase enzymatic assay of as a function of increasing concentrations of
the protein.
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4.4 Investigating Functional Interactions of the DHOase and ATCase Domains of
B. anthracis
The isolated B. anthracis ATCase is catalytically active as is the isolated
DHOase domain. Functional interactions among domains involved in pyrimidine
biosynthesis have been documented in several systems that include that found in
Aquifex aeolicus.19 Therefore, to investigate whether the B. anthracis ATCase and
DHOase domains may influence each other through functional interactions, assays of
ATCase and DHOase were carried out in the presence of both proteins.
4.4.1: Effect of DHOase on the ATCase Activity: The ATCase and DHOase were
mixed in 1:1 molar ratio and incubated on ice for 1hr. The activity of ATCase (Figure
12) in the absence or presence of DHOase was determined by measuring the
formation of carbomyl aspartate from carbamoyl phosphate and aspartate as
described above. The ATCase activity appears to be increased by nearly 2-fold in the
presence of DHOase in a linear fashion.

0.06

umol/min

0.05
0.04

ATC alone
ATC and DHO

0.03

Linear (ATC alone)
Linear (ATC and DHO)

0.02
0.01
0
0

20

40

60

80

100

Protein Sample (uL)

Figure 12: ATCase assay of the B. anthracis ATCase in the absence or in the
presence of equimolar B. anthracis DHOase. The ATCase activity is increased in
the presence of DHOase.
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ATCase assays as a function of increasing carbamoyl phosphate (CP)
concentrations were also carried out (Figure 13). The final concentrations of CP in the
reaction tubes were 0 mM, 0.5 mM, 1 mM, 2 mM, 3 mM, 4 mM, and 5 mM. The
reaction mixtures were allowed to pre-incubate for 20 min at 37oC and then initiated
with 10µl of (0.72 µg/µl) ATCase protein and, in parallel reactions, with an equimolar
concentration of ATCase and DHOase. The reactions were allowed to proceed for 20
min then quenched with 1ml 5% acetic acid, and the absorbance read at 466 nm, as
described above.
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Figure 13: ATCase assay as a function of increasing carbamoyl phosphate
(CP) concentrations of B. anthracis ATCase in the absence (◊) and in the
presence of B. anthracis DHOase (□).

Addition of B. anthracis DHOase resulted in an apparent two-fold activation of
B. anthracis ATCase, suggesting a functional linkage between the two enzymes.
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4.4.2: B. anthracis DHOase Activates B. anthracis ATCase in a 1:1 mole/mole
ratio: A fixed concentration of ATCase (0.86 µg/µl) was titrated with different
concentrations of DHOase (0.60 µg/µl) (DHOase/ATCase: 1:10, 5:10, 10:10, 20:10,
40:10, 60:10, 100:10) in order to find the amount of DHOase needed to activate the
ATCase. The enzyme activity at different protein ratios were assayed as well as
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Figure 14: SDS-PAGE gel and ATCase enzyme assay with a fixed B. anthracis ATCase concentration and
increasing concentrations of B. anthracis DHOase. 1 mole of the DHOase was required to achieve maximal
activation of 1 mole of ATCase. The points on the assay and gel corresponding to an equimolar concentration
of both proteins are boxed.
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visualized by SDS-PAGE (Figure 14). The ATCase activity increases with increasing
concentrations of DHOase and stabilized until the DHOase and ATCase
concentrations were equimolar. Addition of increasing molar concentrations of
DHOase did not result in further activation.

4.5 A. aeolicus DHOase Weakly Activates B. anthracis ATCase
The finding that the B. anthracis ATCase is optimally activated by equimolar
concentrations of B. anthracis DHOase suggests a functional interaction between the
two proteins. To investigate the specificity of this interaction, A. aeolicus DHOase,
which has a high sequence similarity to B. anthracis DHOase, was added at various
molar ratios (Figure 15) to B. anthracis ATCase to examine its ability to activate the
enzyme. A. aeolicus DHOase was able to activate the ATCase from B. anthracis but
much more weakly than the DHOase from B. anthracis. While it took 1 mole of B.
anthracis DHOase to fully activate the ATCase (Figure 14), the enzyme was activated
by only 50% at 25 moles of A. aeolicus DHOase per 1 mole of ATCase. Moreover, full
activation of B. anthracis ATCase required 50 moles of A. aeolicus DHOase. These
results suggest that optimal activation of B. anthracis ATCase is achieved by specific
interactions with B. anthracis DHOase. These interactions appear not to be
conserved in the A. aeolicus enzyme.
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Figure 15: ATCase activity and SDSPAGE of a fixed concentration of B. anthracis ATCase and different
concentrations of A. aeolicus DHOase. A. aeolicus DHOase weakly activates B. anthracis ATCase as
compared to B. anthracis DHOase. The boxed lane on the SDS-gel corresponds to the boxed point on
the assay curve.

4.5.1 Effect of ATCase on DHOase: The DHOase activity of B. anthracis DHOase
was assayed (Figure 16) in the absence or presence of equimolar B. anthracis
ATCase to investigate putative functional interactions between the two domains. The
isolated B. anthracis DHOase was found to be catalytically active in the absence of B.
anthracis ATCase, a situation that differs remarkably from that of A. aeolicus, in which
the isolated DHOase is only active in the presence of the A. aeolicus ATCase
domain.19 Interestingly, the B. anthracis DHOase does not appear to be affected by
the presence of B. anthracis ATCase under these conditions.
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Figure 16: A dihydroorotate saturation curve of B. anthracis DHOase in the absence
or presence of equimolar B. anthracis ATCase. No stimulation of activity is apparent
in the presence of B. anthracis ATCase under these conditions.

4.6: B. anthracis ATCase cannot activate A. aeolicus DHOase
The ATCase from B. anthracis shares a high sequence similarity with the
ATCase from A. aeolicus. The isolated A. aeolicus DHOase is completely inactive
and needs associations with the A. aeolicus ATCase to become catalytically active.
To investigate the specificity of the interactions in B. anthracis, we wanted to examine
whether the A. aeolicus DHOase can be activated by the ATCase from B. anthracis.

A dihydroorotate saturation curve was carried out (Figure 17) to assay for the
activity of isolated A. aeolicus DHOase in the absence or presence of stoichiometric
amounts of A. aeolicus ATCase and B. anthracis ATCase.
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Figure 17: DHOase assay as a function of increasing
dihydroorotate concentration of A. aeolicus DHOase alone (♦), in
the presence of A. aeolicus ATCase (■) or in the presence of B.
anthracis ATCase (▲).

As expected and in accord with previous findings,19 isolated A. aeolicus
DHOase assayed alone showed no catalytic activity unless in the presence of A.
aeolicus ATCase. Interestingly, B. anthracis ATCase was not able to activate the A.
aeolicus DHOase despite its high sequence identity with the A. aeolicus ATCase.

These results clearly show that B. Anthracis ATCase is activated by
stoichiometric amounts of B. anthracis DHOase, while the DHOase is not activated by
ATCase under these assay conditions. The reverse is observed in the A. aeolicus
system. The ATCase domain is not activated by the DHOase, and the isolated A.
aeolicus DHOase is completely inactive in the absence of ATCase despite the
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presence of all the active site residues and metal binding residues needed for
catalysis.

These interactions appear to be highly specific. As mentioned above, the A.
aeolicus DHOase has a high sequence similarity with that of B. Anthracis DHOase
with a percent sequence identity of 43%. However, despite the high sequence
similarity, A. aeolicus DHOase only weakly activated the ATCase from B. anthracis.
Moreover, despite the high sequence similarity of the ATCase from A. aeolicus and B.
anthracis, the B. anthracis ATCase failed to activate the A. aeolicus DHOase.

4.7 Inhibitor Assays
An important objective of studying the B. anthracis pyrimidine enzymes is the
development of drugs that can selectively inhibit the bacterial pathway with minimum
or no effect on the mammalian pathway. The purified DHOase from B. anthracis was
assayed with known inhibitors of DHOases from other organisms: 5-amino orotic acid,
orotic acid, and 5-fluroorotic acid (Figure 18). The assays show that orotate was able
to inhibit B. anthracis DHOase at nanomolar concentrations. However, as orotate is
the product of the next enzyme in the pathway, dihydroorotate dehydrogenase (Figure
2), modified compounds that resemble orotate need to be designed to more
selectively inhibit the dihydroorotase domain, a domain clearly found to be
indispensible for the B. anthracis bacterial growth.
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Figure 18: Inhibition assays of B. anthracis DHOase

4.8 Gel Filtration Chromatography
B. anthracis ATCase, 0.6 ml (0.5 mg) was applied onto an S-300 Sephacryl gel
filtration column, and the protein was eluted with a buffer consisting of 50 mM
Tris/acetate, pH 8.0, 200 mM sodium chloride, and 10% glycerol. Fractions (1 ml)
each were collected and analyzed by SDS-PAGE. Fractions corresponding to the
peak (Figure 19) were tested for enzymatic activity. The peak fractions, lanes 4-6,
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Figure 19: S-300 gel filtration chromatography fractions of B. anthracis ATCase
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showed the highest ATCase activity.
B. anthracis DHOase, 0.6 ml (0.75 mg) was applied to a S-300 Sephacryl gel
filtration column and eluted with a buffer consisting of 50 mM Tris/acetate, pH 8.0, 200
mM sodium chloride, and 10% glycerol (Figure 20). Fractions corresponding to the
peak (Figure 20) were tested for enzymatic activity. The peak fractions, lanes 2-6,
showed the highest DHOase activity.

B. anthracis
DHOase is a
homodimer

Lane:

1

2

3

4

5

6

7

Figure 20: S-300 gel filtration chromatography fractions of B. anthracis DHOase

A stoichiometric mixture of ATCase and DHOase (0.6 ml) was preincubated at
room temperature for 20 min and then loaded onto the S-300 gel filtration column.
The proteins were eluted in a buffer consisting of 50 mM Tris/acetate, pH 8.0, 200 mM
sodium chloride, and 10% glycerol. The fractions were then analyzed using SDSPAGE (Figure 21). Fractions corresponding to the peak (4-7) had both ATCase and
DHOase activities. The two proteins eluted in the same fractions, suggesting
formation of a complex most likely to be a dodecamer consisting of 2 ATCase trimers
and 3 DHOase dimers. This complex likely resembles that found in A. aeolicus.
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Figure 21: S-300 gel filtration chromatography fractions of B. anthracis DHOase and ATCase
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5. Summary

1) S-300 Sephacryl gel filtration chromatography suggests that a complex, likely a
dodecamer, is formed between B. anthracis ATCase and DHOase.

2) Enzyme assays showed that B. anthracis ATCase and B. anthracis DHOase
are active individually and that they do not depend on each other for catalytic
activity.

3) In a stoichiometric complex between B. anthracis ATCase and B. anthracis
DHOase, DHOase appears to activate ATCase by nearly twofold, while
ATCase does not appear to further activate the DHOase.

4) The opposite effect is found in the analogous A. aeolicus system where the
DHOase is completely inactive unless associated with the ATCase domain and
where the ATCase activity is not stimulated by DHOase. This is despite the
high sequence identity between the two enzymes in the two systems.

5) A. aeolicus DHOase can activate B. anthracis ATCase, albeit very weakly.
Much higher molar ratios are required for the observed effects. These results
support the specificity of the interactions between the enzymes in the same
system.

6) Orotate inhibits the B. anthracis DHOase at nanomolar levels. This finding sets
the stage for the development of drugs that can mimic orotate and selectively
inhibit the B. anthracis DHOase.
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6. Future Studies
Determining the three dimensional structure of the B. anthracis DHOaseATCase complex will provide invaluable information of the overall structure and a
close-up view of the active sites. The information obtained will shed light on the
specific functional interactions between the two proteins and aid in the design of
specific inhibitors that will likely result in the development of new therapeutic
approaches to infections resulting from the bacteria, B. anthracis.
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